Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Psoriasis Arthritis, Psoriasis (PsO), Spondylarthropathies
Conditions
Keywords
chronic inflammatory diseases, personalized medicine
Brief summary
Molecular Inflammation Board at the Center for Personalized Medicine
Detailed description
Molecular Inflammation Board at the Center for Personalized Medicine The study objectives are: To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care
Interventions
BIOLOGICALBiologic Agent
Intervention with biologic agents
Sponsors
University Hospital Freiburg
University Hospital Heidelberg
University Hospital Ulm
University Hospital Tuebingen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Chronic inflammatory disorder (PsO, PsA, SpA, IBD) * Given informed consent * 18 years of age
Exclusion criteria
* No capacity to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Therapy persistence | Through study completion, an average of 1 year | Duration of intervention with biological agent |
Countries
Germany
Contacts
Primary ContactNisar P Malek, Prof. Dr.
Outcome results
None listed